IndraLab

Statements

Ibrutinib activates CYLD. 2 / 2

| 2

➶

reach

"BTK inhibitor PCI-32765 promoted CYLD dependent apoptosis in rituximab resistant non-GCB-DLBCL cells."

33827598

➶

reach

"Previous researches in CLL indicated that BTK inhibitor ibrutinib could largely increase CYLD activity through increasing CYLD miRNA transcription, which could inhibit cells proliferation in CLL [XREF_BIBR]."

33827598

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Ibrutinib activates CYLD. 2 / 2

INDRA sources:

Databases

Reading